SUPN Q1 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$144M-6.6% YoY

Gross Profit

$127M88.6% margin

Operating Income

-$3M-2.2% margin

Net Income

$124,0000.1% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-12.6%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$38M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$375M

Stockholders' Equity

$929M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$154M	-6.6%
Gross Profit	$127M	$130M	-2.3%
Operating Income	-$3M	$5M	-160.9%
Net Income	$124,000	$17M	-99.3%

Revenue Segments

Product

$138M49%

Qelbree

$45M16%

Oxtellar X R

$27M10%

GOCOVRI

$27M9%

APOKYN

$17M6%

Trokendi Xr

$16M6%

Manufactured Product, Other

$7M3%

Royalty And License

$5M2%